Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells

Figure 4 Farrerol treatment inhibited ferroptosis in high glucose and free fatty acid treated endothelial cells. A-C: Cell viability was detected via cell counting kit-8 assay in cardiomyocytes, endothelial cells (ECs), and fibroblasts after indicated treatments (n = 6); D-F: Protein expression of GPX4 and xCT were detected in ECs upon high glucose and free fatty acid or different concentration of Farrerol treatment (n = 3); G: Flow cytometry is used to detect the changes in lipid peroxidation levels in ECs under different treatment conditions; H: Relative expression of malondialdehyde in the hearts from indicated groups were determined by the commercial kit (n = 6); I: The content of Fe²⁺ in ECs was assessed by the commercial kit (n = 6). ^aP < 0.05 vs NC; ^bP < 0.05 vs DCM. FA: Farrerol; DCM: Diabetic cardiomyopathy; HG/FFA: High glucose and free fatty acid.